Frequency of TERT promoter mutations in human cancers

Cited by (886)

Items 101–200 of 886

1. Promoter analysis and prediction in the human genome using sequence-based deep learning models
   Ramzan Kh. Umarov, Hiroyuki Kuwahara, Yu Li, Xin Gao, Victor V. Solovyev · 2018 · Bioinformatics
2. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA
   Na Wang, Tiantian Liu, Anastasios Sofiadis, C. Christofer Juhlin, Jan Zedenius, Anders Höög, Catharina Larsson, Dawei Xu · 2014 · Cancer
3. Classification based on mutations ofTERTpromoter andIDHcharacterizes subtypes in grade II/III gliomas
   Pei Yang, Jinquan Cai, Wei Yan, Wei Zhang, Yinyan Wang, Baoshi Chen, Guilin Li, Shouwei Li, Chenxing Wu, Kun Yao et al. · 2016 · Neuro-Oncology
4. Trial Watch: Peptide-based anticancer vaccines
   Jonathan G. Pol, Norma Bloy, Aitziber Buqué, Alexander M.M. Eggermont, Isabelle Cremer, Catherine Sautès‐Fridman, Jérôme Galon, Éric Tartour, Laurence Zitvogel, Guido Kroemer et al. · 2015 · OncoImmunology
5. TERT Promoter Alterations in Glioblastoma: A Systematic Review
   Nathalie Olympios, Vianney Gilard, Florent Marguet, Florian Clatot, Frédéric Di Fiore, Maxime Fontanilles · 2021 · Cancers
6. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC)
   Ying‐Hsia Chu, Dora C. Dias-Santagata, Alexander A. Farahani, Bariş Boyraz, William C. Faquin, Vânia Nosé, Peter M. Sadow · 2020 · Modern Pathology
7. RAS proto-oncogene in medullary thyroid carcinoma
   Margarida M. Moura, Branca Maria Cavaco, Valeriano Alberto Pais Horta Leite · 2015 · Endocrine Related Cancer
8. MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases
   Xue Li Bai, Yan Kong, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Xuan Wang, Lili Mao, Bixia Tang, Siming Li, Bin Lian et al. · 2017 · Clinical Cancer Research
9. Regulatory variants: from detection to predicting impact
   Elena Rojano, Pedro Seoane, Juan A. G. Ranea, James Richard Perkins · 2018 · Briefings in Bioinformatics
10. Papillary Thyroid Cancer Prognosis: An Evolving Field
    Salvatore Ulisse, Enke Baldini, Augusto Lauro, Daniele Pironi, Domenico Tripodi, Eleonora Lori, Iulia Catalina Ferent, Maria Ida Amabile, A Catania, F M Di Matteo et al. · 2021 · Cancers
11. Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization
    Marina Muzza, Carla Colombo, Stefania Rossi, Delfina Tosi, Valentina Cirello, Michela Perrino, Simone De Leo, Elisa Magnani, Elisa Pignatti, Beatrice Vigo et al. · 2014 · Molecular and Cellular Endocrinology
12. Telomere and Telomerase Therapeutics in Cancer
    Yucheng Xu, Amir Goldkorn · 2016 · Genes
13. Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications
    E. R. Matarredona, A. Pastor · 2019 · Frontiers in Oncology
14. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases
    Benjamin Bonhomme, Yann Godbert, Gaëlle Pérot, Abir Al Ghuzlan, Stéphane Bardet, Geneviève Belleannée, Lise Crinière, Christine Do Cao, Geneviève Fouilloux, Serge Guyétant et al. · 2017 · Thyroid
15. TERT promoter mutations and long-term survival in patients with thyroid cancer
    Tae Hyuk Kim, Young-Eun Kim, Soomin Ahn, Ji‐Youn Kim, Chang‐Seok Ki, Young Lyun Oh, Kyunga Kim, Jae Won Yun, Woong‐Yang Park, Jun‐Ho Choe et al. · 2016 · Endocrine Related Cancer
16. Diagnostic, prognostic and predictive relevance of molecular markers in gliomas
    Sebastian Brandner, Andreas von Deimling · 2015 · Neuropathology and Applied Neurobiology
17. Cancer whole-genome sequencing: present and future
    Hidewaki Nakagawa, Christopher P. Wardell, Mayuko Furuta, Hiroaki Taniguchi, Akihiro Fujimoto · 2015 · Oncogene
18. TERT Promoter Mutations in Papillary Thyroid Microcarcinomas
    Dario de Biase, Greta Gandolfi, Moira Ragazzi, Markus Eszlinger, Valentina Sancisi, Mila Gugnoni, Michela Visani, Annalisa Pession, Gian Piero Casadei, Cosimo Durante et al. · 2015 · Thyroid
19. Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer
    Mingzhao Xing · 2016 · BMC Medicine
20. NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings
    Ömer An, Giovanni Marco Dall’Olio, Thanos P. Mourikis, Francesca D. Ciccarelli · 2015 · Nucleic Acids Research
21. Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation
    Naoki Oishi, Tetsuo Kondo, Aya Ebina, Yukiko Sato, Junko Akaishi, Rumi Hino, Noriko Yamamoto, Kunio Mochizuki, Tadao Nakazawa, Hiroshi Yokomichi et al. · 2017 · Modern Pathology
22. MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells
    Li Chai, Xiaojing Kang, Zhenzhu Sun, Mingfeng Zeng, Shirong Yu, Yuan Ding, Junqin Liang, Tingting Li, Juan Zhao · 2018 · Cancer Management and Research
23. A second chance for telomerase reverse transcriptase in anticancer immunotherapy
    Maurizio Zanetti · 2016 · Nature Reviews Clinical Oncology
24. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy
    Ren‐Chin Wu, A. Ayhan, Daichi Maeda, Kyu-Rae Kim, Blaise Alexander Clarke, Patricia H. Shaw, Michael Herman Chui, Barry P. Rosen, Ie‐Ming Shih, Tian‐Li Wang · 2013 · The Journal of Pathology
25. A Pharmacological Chaperone Molecule Induces Cancer Cell Death by Restoring Tertiary DNA Structures in Mutant hTERT Promoters
    Hyun-Jin Kang, Yunxi Cui, Holly Yin, Amy Scheid, William P.D. Hendricks, Jessica E. Schmidt, Aleksandar Sekulić, De‐Ming Kong, Jeffrey M. Trent, Vijay M. Gokhale et al. · 2016 · Journal of the American Chemical Society
26. The hTERT core promoter forms three parallel G-quadruplexes
    Robert C. Monsen, Lynn W. DeLeeuw, William L. Dean, Robert D. Gray, Thomas Michael Sabo, Srinivas Chakravarthy, Jonathan Brad Chaires, John O. Trent · 2020 · Nucleic Acids Research
27. TERT promoter mutations in primary liver tumors
    Jean‐Charles Nault, Jessica Zucman‐Rossi · 2015 · Clinics and Research in Hepatology and Gastroenterology
28. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences
    Barbara Heidenreich, P. Sivaramakrishna Rachakonda, Md. Ismail Hosen, Florian Volz, Kari Hemminki, Astrid Weyerbrock, Rajiv Kumar · 2015 · Oncotarget
29. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities
    Christian Koelsche, Marcus Renner, Wolfgang Hartmann, Regine Brandt, Burkhard Lehner, Nina Waldburger, Ingo Alldinger, Thomas Schmitt, Gerlinde Egerer, Roland Penzel et al. · 2014 · Journal of Experimental & Clinical Cancer Research
30. TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
    Klaus Griewank, Rajmohan Murali, Bastian Schilling, Tobias T. Schimming, Inga Möller, Iris Moll, Marion Schwamborn, Antje Sucker, Lisa Zimmer, Dirk Schadendorf et al. · 2013 · PLoS ONE
31. Telomeres and Age-Related Diseases
    Hans‐Jürgen Gruber, Maria Donatella Semeraro, Wilfried Renner, Markus Herrmann · 2021 · Biomedicines
32. A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression
    Linghe Xi, Jens C. Schmidt, Arthur J. Zaug, Dante Ascarrunz, Thomas R. Cech · 2015 · Genome biology
33. TERT promoter mutations and monoallelic activation of TERT in cancer
    Franklin W. Huang, Craig M. Bielski, Mikael L. Rinne, William C. Hahn, William R. Sellers, Frank P. Stegmeier, Levi A. Garraway, Gregory V. Kryukov · 2015 · Oncogenesis
34. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy
    Rengyun Liu, M. Xing · 2014 · Endocrine Related Cancer
35. Diagnostic potential of TERT promoter and FGFR 3 mutations in urinary cell‐free DNA in upper tract urothelial carcinoma
    Yujiro Hayashi, Kazutoshi Fujita, Kyosuke Matsuzaki, Makoto Matsushita, Norihiko Kawamura, Yoko Koh, Kosuke Nakano, Cong Wang, Yu Ishizuya, Yoshiyuki Yamamoto et al. · 2019 · Cancer Science
36. Prevalence and Implications of TERT Promoter Mutation in Uveal and Conjunctival Melanoma and in Benign and Premalignant Conjunctival Melanocytic Lesions
    Anna E. Koopmans, Kimberley Ober, Hendrikus Jan Dubbink, Dion A. Paridaens, Nicole C. Naus, Stephan Belunek, Bart Krist, Edward Post, Ellen C. Zwarthoff, Annelies de Klein et al. · 2014 · Investigative Ophthalmology & Visual Science
37. TERT biology and function in cancer: beyond immortalisation
    Ana Pestana, João Vinagre, Manuel A. Sobrinho-Simões, Paula Soares · 2017 · Journal of Molecular Endocrinology
38. Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis
    Jing Yang, Yanping Gong, Shuping Yan, Hui Chen, Siqin Qin, Rixiang Gong · 2019 · Endocrine
39. Distinguishing Nested Variants of Urothelial Carcinoma From Benign Mimickers by TERT Promoter Mutation
    Minghao Zhong, Wei Tian, Jian Zhuge, Xiaoyong Zheng, Tiangui Huang, Dongming Cai, David Zhang, Ximing J. Yang, Pedram Argani, John T. Fallon et al. · 2014 · The American Journal of Surgical Pathology
40. TERT Promoter Mutations in Thyroid Cancer
    Ali Saeed Alzahrani, Rawan Al-Saadi, Avaniyapuram Kannan Murugan, Bakr Bin Sadiq · 2016 · Hormones and Cancer
41. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
    Stanley Zhou, Aislinn E. Treloar, Mathieu Lupien · 2016 · Cancer Discovery
42. Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study
    Rui Batısta, João Vinagre, Hugo Prazeres, Cristina Sampaio, João Pedro Peralta, Paulo Conceição, Amílcar Sismeiro, Ricardo Romao Nazario Leao, Andreia Gomes, F. Furriel et al. · 2019 · Frontiers in Genetics
43. TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
    Koushik Muralidharan, Anudeep Yekula, Julia L. Small, Zachary S. Rosh, Keiko M. Kang, Lan Wang, Spencer Lau, Hui Zhang, Hakho Lee, Chetan Bettegowda et al. · 2020 · Clinical Cancer Research
44. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors
    Tiantian Liu, Taylor C. Brown, C. Christofer Juhlin, Adam Stenman, Na Wang, Martin Bäckdahl, James Michael Healy, Manju Lata Prasad, Reju M. Korah, Tobias Carling et al. · 2014 · Endocrine Related Cancer
45. Association ofTERTPromoter Mutation 1,295,228 C>T WithBRAFV600E Mutation, Older Patient Age, and Distant Metastasis in Anaplastic Thyroid Cancer
    Xiaoguang Shi, Rengyun Liu, Shen Qu, Guangwu Zhu, Justin A. Bishop, Xiaoli Liu, Hui Sun, Zhongyan Shan, Enhua Wang, Yahong Luo et al. · 2015 · The Journal of Clinical Endocrinology & Metabolism
46. Whole-Genome Sequencing in Cancer
    Eric Y. Stutheit-Zhao, Martin R. Jones, Steven J.M. Jones · 2018 · Cold Spring Harbor Perspectives in Medicine
47. The Drivers, Mechanisms, and Consequences of Genome Instability in HPV-Driven Cancers
    Vanessa Porter, Marco A. Marra · 2022 · Cancers
48. Pathogenesis of cancers derived from thyroid follicular cells
    James A. Fagin, Gnana Prakasam Krishnamoorthy, Iñigo Landa · 2023 · Nature reviews. Cancer
49. TERT promoter mutation in adult granulosa cell tumor of the ovary
    Jessica A. Pilsworth, Dawn R. Cochrane, Zhouchunyang Xia, Geraldine Aubert, Anniina Färkkilä, Hugo M. Horlings, Satoshi Yanagida, Winnie Yang, Jamie L. Lim, Yi Kan Wang et al. · 2018 · Modern Pathology
50. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome
    Kristine S. Wong, Fei Dong, Milhan Telatar, Jochen H. Lorch, Erik Karl Alexander, Ellen Marqusee, Nancy L. Cho, Matthew Alexander Nehs, Gerard M. Doherty, Michelle Afkhami et al. · 2020 · Thyroid
51. A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
    Glodzik, Dominik, Morganella, Sandro, Davies, Helen, Simpson, Peter T, Li, Yilong, Zou, Xueqing, Diez-Perez, Javier, Staaf, Johan, Alexandrov, Ludmil B, Smid, Marcel et al. · 2017 · Nature Genetics
52. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT
    Matthias S. Dettmer, Anja Maria Schmitt, Hans C. Steinert, David Capper, Holger Moch, Paul Komminoth, Aurel A. Perren · 2015 · Endocrine Related Cancer
53. Molecular Genomic Profiling of Melanocytic Nevi
    Andrew J. Colebatch, Peter M. Ferguson, Felicity Newell, Stephen H. Kazakoff, Tom Witkowski, Alexander Dobrovic, Peter A. Johansson, Robyn P.M. Saw, Jonathan R. Stretch, Grant A. McArthur et al. · 2019 · Journal of Investigative Dermatology
54. Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
    Yanni Ma, Ronghui Xia, Xuhui Ma, Robert L. Judson‐Torres, Hanlin Zeng · 2021 · Frontiers in Oncology
55. G-quadruplex DNA: A Longer Story
    Robert C. Monsen, John O. Trent, Jonathan Brad Chaires · 2022 · Accounts of Chemical Research
56. Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations
    Lindley A. Maryoung, Yangbo Yue, Ashley M. Young, Chad A. Newton, Cindy Barba, Nicolai S. C. van Oers, Richard C. Wang, Christine Kim Garcia · 2017 · Journal of Clinical Investigation
57. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer
    Federica Panebianco, Alyaksandr V. Nikitski, Marina N. Nikiforova, Yuri E. Nikiforov · 2019 · Cancer Medicine
58. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome
    Catarina Tavares, Miguel Melo, José Cameselle‐Teijeiro, Paula Soares, Manuel A. Sobrinho-Simões · 2015 · European Journal of Endocrinology
59. Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential
    Stina George Fernandes, Rebecca Dsouza, Gouri Pandya, Anuradha Kirtonia, Vinay Tergaonkar, Sook Y. Lee, Manoj Garg, Ekta Khattar · 2020 · Cancers
60. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features
    Catarina Tavares, Maria João Coelho, Catarina Eloy, Miguel Melo, Adriana Gaspar da Rocha, Ana Pestana, Rui Batısta, Luciana Bueno Ferreira, Elisabete Rios, Samia Selmi‐Ruby et al. · 2018 · Endocrine Connections
61. Predictive factors of outcome in poorly differentiated thyroid carcinomas
    Christelle de la Fouchardière, Myriam Decaussin‐Petrucci, Julien Berthiller, Françoise Descôtes, Jonathan Lopez, Jean‐Christophe Lifante, Jean‐Louis Peix, Anne‐Laure Giraudet, Armelle Delahaye, Sandrine Masson et al. · 2018 · European Journal of Cancer
62. Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options
    Niels J. Brouwer, Robert M. Verdijk, Steffen Heegaard, Marina Marinkovic, Bita Esmaeli, Martine Johanna Jager · 2021 · Progress in Retinal and Eye Research
63. Telomere Maintenance Mechanisms in Cancer: Clinical Implications
    Roger R. Reddel · 2014 · Current Pharmaceutical Design
64. Reconstructing the molecular life history of gliomas
    Floris P Barthel, Pieter Wesseling, Roel G.W. Verhaak · 2018 · Acta Neuropathologica
65. Bring It to an End: Does Telomeres Size Matter?
    Camille Laberthonnìère, Frédérique Magdinier, Jérôme D. Robin · 2019 · Cells
66. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas
    Martyn Bullock, Yan Ren, Christine J. O’Neill, Anthony James Gill, Adam Aniss, Mark S. Sywak, Stan B. Sidhu, Leigh Delbridge, Diana Learoyd, Florent de Vathaire et al. · 2015 · Clinical Endocrinology
67. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer
    Ricardo Romao Nazario Leao, Donghyun Lee, Arnaldo Figueiredo, Thomas Hermanns, Peter Johannes Wild, Martin Komosa, Irene Lau, M. Mistry, Nuno Miguel Nunes, Aryeh Joshua Price et al. · 2018 · International Journal of Cancer
68. Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation
    Nighat Noureen, Shaofang Wu, Yingli Lv, Juechen Yang, W.K. Alfred Yung, Jonathan Gelfond, Xiaojing Wang, Dimpy Koul, Andrew T. Ludlow, Siyuan Zheng · 2021 · Nature Communications
69. Cribriform-morular variant of papillary thyroid carcinoma: a distinctive type of thyroid cancer
    Alfred King-yin Lam, Nassim Saremi · 2017 · Endocrine Related Cancer
70. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas
    Kun Wang, Tiantian Liu, Li Liu, Jikai Liu, Cheng Liu, Chang Wang, Nan Ge, Hongbo Ren, Keqiang Yan, Sanyuan Hu et al. · 2014 · Oncotarget
71. LARVA: an integrative framework for large-scale analysis of recurrent variants in noncoding annotations
    Lucas Lochovsky, Jing Zhang, Yao Fu, Ekta Khurana, Mark Gerstein · 2015 · Nucleic Acids Research
72. A six-genotype genetic prognostic model for papillary thyroid cancer
    Xiaopei Shen, Rengyun Liu, Mingzhao Xing · 2016 · Endocrine Related Cancer
73. Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors
    Parisa Mazrooei, Ken J. Kron, Yanyun Zhu, Stanley Zhou, Giacomo Grillo, Tahmid Mehdi, Musaddeque Ahmed, Tesa Severson, Paul Guilhamon, Nicholas Sinnott Armstrong et al. · 2019 · Cancer Cell
74. The mTOR pathway is necessary for survival of mice with short telomeres
    Iole Ferrara‐Romeo, Paula Martínez, Sarita Saraswati, Kurt Whittemore, Osvaldo Graña‐Castro, Lydia Thelma Poluha, Rosa Serrano, Elena Hernández-Encinas, Carmen Blanco‐Aparicio, Juana María Flores et al. · 2020 · Nature Communications
75. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas
    Ke Gao, Gang Li, Yiping Qu, Maode Wang, Bo Cui, Meiju Ji, Bingyin Shi, Peng Hou · 2015 · Oncotarget
76. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities
    Matthew D. Wood, Aaron M. Halfpenny, Stephen R. Moore · 2019 · Diagnostic Pathology
77. Identification of Cancer Drivers at CTCF Insulators in 1,962 Whole Genomes
    Eric Minwei Liu, Alexander Martinez‐Fundichely, Bianca Jay Diaz, Boaz E. Aronson, Tawny N. Cuykendall, Matthew J. MacKay, Priyanka Dhingra, Elissa W.P. Wong, Ping Chi, Effie Apostolou et al. · 2019 · Cell Systems
78. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression
    Xiaotian Yuan, Ninni Mu, Na Wang, Klas Strååt, Anastasios Sofiadis, Yanxia Guo, Adam Stenman, Kailin Li, Guanghui Cheng, Lu Zhang et al. · 2018 · Oncogene
79. Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives
    Ulrich Thorsten Hacker, Martin Bentler, Dorota Kaniowska, Michael Alexander Morgan, Hildegard Büning · 2020 · Cancers
80. Human TERT promoter mutations as a prognostic biomarker in glioma
    Branka Powter, Sarah A. Jeffreys, Heena Sareen, Adam James Cooper, Daniel Brungs, Joseph William Po, Tara Laurine Roberts, Eng‐Siew Koh, Kieran F. Scott, Mila Sajinovic et al. · 2021 · Journal of Cancer Research and Clinical Oncology
81. Telomere Length Dynamics and the Evolution of Cancer Genome Architecture
    Kez Cleal, Kevin Norris, Duncan M. Baird · 2018 · International Journal of Molecular Sciences
82. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness
    Elisabetta Macerola, Barbara Loggini, Riccardo Giannini, Giulia GARAVELLO, Mirella Giordano, Agnese Proietti, Cristina Niccoli, Fulvio Basolo, Gabriella Fontanini · 2015 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
83. Frequency of TERT promoter mutations in primary tumors of the liver
    Quaas, Alexander, Oldopp, Theresa, Tharun, Lars, Klingenfeld, Catina, Krech, Till, Sauter, Guido, Grob, Tobias J. · 2014 · Virchows Archiv
84. Hereditary melanoma: Update on syndromes and management
    Efthymia Soura, Philip J. Eliades, Kristen Shannon, Alexander Stratigos, Hensin Tsao · 2016 · Journal of the American Academy of Dermatology
85. Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review
    Brittany Avin McKelvey, Christopher B. Umbricht, Martha A. Zeiger · 2020 · Frontiers in Endocrinology
86. Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas
    Daniel J. Brat, Kenneth Aldape, Julia A. Bridge, Peter Canoll, Howard Colman, Meera R. Hameed, Brent T. Harris, Eyas M. Hattab, Jason T. Huse, Robert Brian Jenkins et al. · 2022 · Archives of Pathology & Laboratory Medicine
87. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors
    Jingjing Jiao, Gordon P. Watt, Heather L. Stevenson, Tiffany L. Calderone, Susan P. Fisher‐Hoch, Yuanqing Ye, Xifeng Wu, John Moore Vierling, Laura Beretta · 2018 · Hepatology Communications
88. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer
    Young Shin Song, Seong‐Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su‐jin Kim, Sun Wook Cho, Kyu Eun Lee, Jeong‐Sun Seo et al. · 2019 · Endocrine Related Cancer
89. The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma
    Laura-Marie Ammer, Arabel Vollmann‐Zwerenz, Viktoria Ruf, Christian H. Wetzel, Markus J. Riemenschneider, Nathalie L. Albert, Philipp Beckhove, Peter Hau · 2020 · Cancers
90. Personalized Therapy in Patients With Anaplastic Thyroid Cancer: Targeting Genetic and Epigenetic Alterations
    Neal Patrick Smith, Carmelo Nucera · 2014 · The Journal of Clinical Endocrinology & Metabolism
91. TERT mRNA Expression as a Novel Prognostic Marker in Papillary Thyroid Carcinomas
    Aya Tanaka, Michiko Matsuse, Vladimir Saenko, Tomoe Nakao, Kosho Yamanouchi, Chika Sakimura, Hiroshi Yano, Eijun Nishihara, Mitsuyoshi Hirokawa, Keiji Suzuki et al. · 2019 · Thyroid
92. In perspective: An update on telomere targeting in cancer
    Eric T. Sugarman, Gao Zhang, Jerry W. Shay · 2019 · Molecular Carcinogenesis
93. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
    Ja Seong Bae, Yourha Kim, Sora Jeon, Se Hee Kim, Tae Jung Kim, Sohee Lee, Min‐Hee Kim, Dong Jun Lim, Youn Soo Lee, Chan Kwon Jung · 2016 · Diagnostic Pathology
94. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors
    Michiko Matsuse, Tomonori Yabuta, Vladimir Saenko, Mitsuyoshi Hirokawa, Eijun Nishihara, Keiji Suzuki, Shunichi Yamashita, Akira Miyauchi, Norisato Mitsutake · 2017 · Scientific Reports
95. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes
    Gustavo Penna, Fernanda Vaisman, Mário Vaisman, Manuel A. Sobrinho-Simões, Paula Soares · 2016 · Cytogenetic and Genome Research
96. Current Insights to Regulation and Role of Telomerase in Human Diseases
    Mert B. Ozturk, Yinghui Li, Vinay Tergaonkar · 2017 · Antioxidants
97. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis
    Çagatay Güneş, Felix Wezel, Jennifer Southgate, Christian Bolenz · 2018 · Nature Reviews Urology
98. Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme
    Corey Smith, Katie E. Lineburg, José Paulo Martins, George R. Ambalathingal, Michelle A. Neller, Beth Morrison, Katherine K. Matthews, Sweera Rehan, Pauline Crooks, Archana Panikkar et al. · 2020 · Journal of Clinical Investigation
99. Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma
    Neerav Narendra Shukla, Stephen S. Roberts, Mollah Obayedullah Baki, Qazi Danish Mushtaq, Paul Edward Goss, Ben Ho Park, Gunes Gundem, Ken Tian, Heather M. Geiger, Kristie Redfield et al. · 2017 · JCO Precision Oncology
100. Genomic Hallmarks of Thyroid Neoplasia
     Thomas J. Giordano · 2017 · Annual Review of Pathology Mechanisms of Disease